T6192

Alogliptin (SYR-322)(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10, 000-fold selectivity over DPP-8 and DPP-9.

α- Synuclein inhibitor 7 (compound 3gf) is effective α- Synuclein ( α- Syn) aggregation inhibitor, IC50 is 1.95 μM, inhibition rate at 30μM was 85.8%. α- Synuclein inhibitor 7 has blood-brain barrier permeability.

Ambrosentan (BSF 208075) sodium is a selective and oral effective antagonist of ET type A receptor ( ETAR ).

CDK7-IN-12 is an effective CDK7 inhibitor and plays a key role in regulating transcription and cell cycle. CDK7-IN-12 can effectively inhibit the proliferation of malignant tumors in vitro and in vivo. CDK7-IN-12 has research potential in cancer diseases.

ERRα antagonist-2 (Compound 11) is an estrogen-related receptor α inverse agonist with an IC50 of 0.80 μM, capable of inhibiting migration and invasion in ER-negative MDA-MB-231 cells and suppressing breast cancer growth.

NMDA receptor regulator 6 (Compound 183) is an effective NMDA receptor regulator and has research value in neurological disorders.

AKR1C3-IN-7 (Compound 13) is a potent and selective AKR1C3 inhibitor with an IC50 of 0.19 μM, exhibiting antitumor activity.

AKR1C3-IN-8 (Compound 5) is a potent and selective AKR1C3 inhibitor (IC50 = 0.069 μM) with demonstrated antitumor activity.

hDDAH-1-IN-2 is a selective, orally active inhibitor of [human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1)] with an excellent cell toxicity/viability profile.

Antitubercular agent-25 (Compound 28) is an anti-tubercular agent with an extracellular IC50 of 0.42 μM and an intracellular IC50 of 0.20 μM against M. tuberculosis H37Rv, and it demonstrates good metabolic stability.

PD-1/PD-L1-IN-14 (compound 17) is an inhibitor of PD-1/PD-L1 interaction (IC50=27.8 nM) that promotes PD-L1 dimerization, endocytosis, and degradation.

Alogliptin-13CD3 is the deuterium-labeled Alogliptin. Alogliptin (T6192) is a selective inhibitor of DPP-4.